SCHEMBL892373

SCHEMBL892373

CCOC(=O)c1ncc(-c2ccccc2)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.52
CES1 P23141 2/20 0.52
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
ATM Q13315 1/20 0.49
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111489 0.87 CDC7 (0.53) FAAHALDH1A1KDM4EHPGDKMT2A
SCHEMBL5111369 0.86 FAAH (0.56) FAAHALDH1A1KDM4EHPGDKMT2A
SCHEMBL6819068 0.86 FAAH (0.49) FAAHALDH1A1KDM4EHPGDKMT2A
SCHEMBL11557808 0.86 TARBP2 (0.53) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL31301564 0.86 TARBP2 (0.53) ALDH1A1KDM4EHPGDKMT2AHSD17B10
SCHEMBL6919654 0.85 TARBP2 (0.54) FAAHKMT2ASMN1; SMN2MAPTTARBP2
SCHEMBL25206936 0.84 HDAC1 (0.52) FAAHHPGDNPC1RAB9ATP53
SCHEMBL6494800 0.84 HDAC1 (0.52) KMT2ASMN1; SMN2MAPTTP53HDAC1
SCHEMBL30473951 0.84 HDAC1 (0.52) FAAHHPGDNPC1RAB9ATP53
SCHEMBL30975798 0.84 HDAC1 (0.52) KMT2ASMN1; SMN2MAPTTP53HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
US-20240294876-A1 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF UNIV SOUTHERN CALIFORNIA (US) 2024-09-05 US disclosed
US-11958833-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-04-16 US disclosed
EP-4341386-A2 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF University of Southern California (US) 2024-03-27 EP disclosed
CN-117751182-A Method for amplifying human granulocyte-macrophage progenitor cells and application thereof 南加利福尼亚大学 2024-03-22 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO disclosed
US-6562816-B2 Alpha 7 nicotine acetylcholine receptor agonist anti-psychotic agent, with reduced side effects PHARMACIA & UPJOHN COMPANY 2003-05-13 US disclosed
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed
WO-2003018585-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-03-06 WO disclosed
US-5776933-A Method of inhibiting protease E. R. SQUIBB & SONS, INC. (US) 1998-07-07 US disclosed
US-5760036-A ENZYME INHIBITORS OF RETROVIRAL PROTEASE FOR PREVENTION OF AIDS E. R. SQUIBB & SONS, INC. (US) 1998-06-02 US disclosed
US-5559256-A Aminediol protease inhibitors E. R. SQUIBB & SONS, INC. (US) 1996-09-24 US disclosed
EP-0580402-A2 Aminediol protease inhibitors E.R. SQUIBB & SONS, INC. (US) 1994-01-26 EP disclosed
US-4636462-A PHOTOTHERMOGRAPHY; STORAGE STABLE BASE PRECURSOR FUJI PHOTO FILM CO., LTD. (JP) 1987-01-13 US disclosed
US-4620010-A Process for preparing carboalkoxy substituted benzoxazole compounds USV PHARMACEUTICAL CORP. (US) 1986-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 FAAH 3507/4885CES1 2453/4885ALDH1A1 2569/4885
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE SULT1E1, UGT1A7, UGT1A1 FAAH 2042/4885CES1 22/4885ALDH1A1 1238/4885
US-11958833-B2 Compounds USP30, USP20, USP10 FAAH 2800/4885CES1 862/4885ALDH1A1 1021/4885
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D FAAH 3489/4885CES1 2548/4885ALDH1A1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.